FXS5626 Phase II Trial for Non-Infectious Uveitis (NIU)
ClinicalTrials.gov Studies
Summary
A Phase II clinical trial (NCT07552012) evaluating the efficacy and safety of oral FXS5626 tablets versus placebo in patients with active, non-anterior (intermediate, posterior, or pan) non-infectious uveitis (NIU). The trial is registered with ClinicalTrials.gov and lists three study arms: two FXS5626 tablet arms and one placebo arm. Participants must have active non-infectious uveitis affecting the intermediate, posterior, or panuveitis segments of the eye.
“The purpose of this study is to find out the efficacy and safety of oral FXS5626 in participants with active, non-anterior (intermediate, posterior, or pan) non-infectious uveitis (NIU).”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
A Phase II clinical trial (NCT07552012) has been registered on ClinicalTrials.gov for the investigation of FXS5626 oral tablets in patients with active non-anterior non-infectious uveitis (NIU). The trial will study two FXS5626 dosing arms compared to placebo. Non-infectious uveitis is an inflammatory eye condition affecting the intermediate, posterior, or panuveitis segments.\n\nPharmaceutical sponsors and clinical investigators conducting ocular drug development should note this trial registration as it represents an active development candidate in the NIU indication space. The trial's existence indicates a drug developer has progressed FXS5626 beyond preclinical or Phase I stages for this specific uveitis subtype.
Archived snapshot
Apr 27, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
A Phase II Clinical Trial to Evaluate the Efficacy and Safety of FXS5626 in Patients With NIU
Phase 2 NCT07552012 Kind: PHASE2 Apr 27, 2026
Abstract
The purpose of this study is to find out the efficacy and safety of oral FXS5626 in participants with active, non-anterior (intermediate, posterior, or pan) non-infectious uveitis (NIU).
Conditions: Active Non-anterior, Non-infectious Uveitis
Interventions: FXS5626 tablet, FXS5626 tablet, Placebo
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.